New yellow fever vaccine shows promise in early human trial

NCT ID NCT02743455

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tested a new yellow fever vaccine (MVA-BN-YF) in 92 healthy adults aged 18-45. Some volunteers received the vaccine alone, some with an adjuvant (ISA 720) to boost the immune response, and others received a placebo or a different vaccine. The main goal was to check safety and how well the body's immune system responds. Since this is a Phase I trial, it is too early to know if the vaccine will prevent yellow fever.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MVA-BN Yellow Fever Vaccine with or without Montanide ISA 720 adjuvant
What this could lead to
If successful, this could lead to a new, safer yellow fever vaccine that may be easier to produce and distribute.
What could go wrong
This is an early Phase I trial with only 92 people, so it is too soon to know if the vaccine works. Side effects are possible, and the results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for YELLOW FEVER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Saint Louis University Center for Vaccine Development

    St Louis, Missouri, 63104-1015, United States

  • University of Iowa - Vaccine Research and Education Unit

    Iowa City, Iowa, 52242-2600, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.